



## **COR-003 Phase 3 Study Protocol to be Presented at ENDO 2015: The Endocrine Society's 97<sup>th</sup> Annual Meeting & Expo**

**January 29, 2015 -- Radnor, Penn., U.S. and Göteborg, Sweden -- [Cortendo AB](#)** [ticker: CORT on NOTC-A], a global biopharmaceutical company initially focused on orphan endocrine disorders, today announced that it will present the study protocol of its global Phase 3 study of COR-003 in patients with endogenous Cushing's syndrome at ENDO 2015: The Endocrine Society's 97<sup>th</sup> Annual Meeting & Expo March 5-8 in San Diego, CA. This abstract will also be published in the April issue of *Endocrine Reviews*.

Additional information on the Cortendo presentation:

**Title:** [An Open-label Study to Assess the Safety and Efficacy of Levoketoconazole \(COR-003\) in the Treatment of Endogenous Cushing's Syndrome](#)

**Abstract:** 20580

**Presentation Date and Time:** Friday, March 6, 2015, 1 – 3 p.m.

**Location:** Poster session, Expo Hall, San Diego Convention Center

**Posterboard:** FRI-376

This abstract is available online:

<https://endo.confex.com/endo/2015endo/webprogram/Paper20580.html>

### **About Cortendo AB**

Cortendo AB is a global biopharmaceutical company incorporated in Sweden and based in the United States. The Company's initial strategic focus is to be the global leader in commercializing innovative medicines for orphan endocrine disorders. Cortendo is leading the way in the field of cortisol inhibition through the investigational drug, COR-003 (levoketoconazole) currently being studied in the global Phase 3 SONICS trial for the treatment of Cushing's syndrome. COR-003 (levoketoconazole) has received orphan designation from both the European Medicines Agency (EMA) and the U.S. Food and Drug Administration (FDA). The Company's intent is to independently commercialize its Orphan/Endocrine assets in key global markets, and partner non-strategic product opportunities, such as diabetes, at relevant development stages.

###

For more information, contact:

### **Corporate:**

Ruth Thieroff-Ekerdt, Chief Medical Officer

Office : 610-254-9200

[rekerdt@cortendo.com](mailto:rekerdt@cortendo.com)

**Investors:**

**LaVoieHealthScience**

Donna LaVoie

617-374-8800, Ext. 107

[dlavoie@lavoiehealthscience.com](mailto:dlavoie@lavoiehealthscience.com)

**Media:**

**LaVoieHealthScience**

David Connolly

617-374-8800, Ext. 108

[dconnolly@lavoiehealthscience.com](mailto:dconnolly@lavoiehealthscience.com)

**Sweden:**

Box 47

SE-433 21 Partille

Tel. / Fax. +46 (0)31-263010

**USA:**

555 East Lancaster Ave.

Suite 510

Radnor, PA 19087

Tel. +1 610-254-9200

Fax. +1 610-254-8005